Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR1 | Q92633 | 2/20 | 0.39 |
| ▸ | LPAR5 | Q9H1C0 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 6/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.36 |
| ▸ | LMNA | P02545 | 3/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | MET | P08581 | 2/20 | 0.34 |
| ▸ | AXL | P30530 | 1/20 | 0.34 |
| ▸ | MERTK | Q12866 | 1/20 | 0.34 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7692498 | 0.94 | LPAR1 (0.39) | LPAR1LPAR5POLBALDH1A1MAPK1 | |
| SCHEMBL7686348 | 0.91 | ALDH1A1 (0.43) | POLBALDH1A1MAPK1MEN1KMT2A | |
| SCHEMBL7693571 | 0.87 | LPAR1 (0.39) | LPAR1LPAR5POLBALDH1A1MAPK1 | |
| SCHEMBL6487652 | 0.86 | ALDH1A1 (0.43) | POLBALDH1A1MAPK1MEN1KMT2A | |
| SCHEMBL7686564 | 0.85 | LPAR1 (0.43) | LPAR1LPAR5POLBALDH1A1MAPT | |
| SCHEMBL7694477 | 0.84 | MET (0.44) | LPAR1LPAR5ALDH1A1MAPTMEN1 | |
| SCHEMBL6488702 | 0.83 | LPAR1 (0.39) | LPAR1LPAR5POLBALDH1A1MAPK1 | |
| SCHEMBL7686800 | 0.83 | ADRB1 (0.39) | POLBALDH1A1MAPK1GAAMAPT | |
| SCHEMBL7692913 | 0.82 | LPAR1 (0.39) | LPAR1LPAR5POLBALDH1A1MAPK1 | |
| SCHEMBL7692473 | 0.82 | MET (0.38) | LPAR1LPAR5POLBALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050043358-A1 | Aminoalcohol derivatives and their use as beta 3 adrenergic agonists | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2005-02-24 | — | — | US | disclosed |
| US-20020143034-A1 | Aminoalcohol derivatives and their use as beta 3 adrenergic agonists | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2002-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020143034-A1 | Aminoalcohol derivatives and their use as beta 3 adrenergic agonists | ADRB1, ADRB2, ADRB3 | LPAR1 494/4885LPAR5 1445/4885POLB 2187/4885 |
| US-20050043358-A1 | Aminoalcohol derivatives and their use as beta 3 adrenergic agonists | ADRB2, ADRB1, ADRB3 | LPAR1 361/4885LPAR5 1228/4885POLB 2612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.